TransMedics Group, Inc. (TMDX) fair value analysis
Nasdaq · Updated 2026-09-07
TransMedics Group, Inc. is a medical device company that develops and commercializes organ preservation and transport systems designed to extend the viability of organs for transplantation. The company operates internationally, serving transplant centers and organ procurement organizations in multiple countries.
Forward Fair Value verdict
UndervaluedBased on TickrTrends' weekly Forward Fair Value model, TMDX is trading at more than a 25% discount to estimated fair value.
TMDX currently ranks #27 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.
- Last price
- $81.55
- Sector
- Healthcare
- 12-month range
- $67.53–$150.42
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- A
- Momentum grade
- B
- Leverage
- Moderate
- Margin trend
- Stable
- Revenue growth
- High
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
What our data shows for TMDX
- Our model validated 7 trailing price-to-earnings windows for TMDX, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $67.53–$150.42.
- The 14-day relative strength index sits at a neutral 63.
- 3 of the last 12 weekly snapshots showed positive price momentum.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TMDX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent TMDX news
TickrTrends' derived news-sentiment signal for TMDX is currently leaning positive, computed from recent coverage.
- TransMedics: Slowing Growth Brings Its Valuation Into Question (NASDAQ:TMDX) (seekingalpha.com, 2026-09-08)
TickrTrends take: TransMedics operates in the Healthcare sector where growth trajectories significantly influence valuation multiples, making the reported slowdown in growth relevant to how the company's current metrics are assessed. TickrTrends currently derives an Undervalued verdict for TMDX, which suggests the market price may not fully reflect the company's fundamentals despite recent growth deceleration. Investors focused on valuation should monitor whether the growth slowdown represents a temporary adjustment or signals a more sustained shift in the company's expansion rate, as this distinction will be critical to determining if the undervalued assessment remains justified. - TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investors (gurufocus.com, 2026-09-04)
TickrTrends take: TransMedics Group Inc operates in the Healthcare sector, where valuation metrics become particularly important given the capital-intensive nature of medical device development and commercialization. According to TickrTrends' current assessment, TMDX is considered undervalued, which aligns with investor interest reflected in recent price movements. A GF Score of 69 suggests moderate fundamental quality that warrants attention from valuation-focused investors monitoring whether the current undervaluation thesis remains sustainable as the company executes its business strategy. - Is TransMedics Group Inc (TMDX) a Bargain After 4.0% Drop? GF Value Says Undervalued (gurufocus.com, 2026-08-31)
TickrTrends take: TransMedics Group Inc operates in the Healthcare sector and has recently experienced a 4 percent decline in share price. TickrTrends currently derives an undervalued verdict for TMDX, which aligns with valuation assessments suggesting the stock may offer value at present levels. Investors focused on valuation metrics should monitor whether the company's fundamentals and growth prospects justify this undervalued assessment or if further price movement occurs.
What people are saying
Follow the TMDX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — TMDX's momentum indicator declined from A to B this week, reflecting a shift toward weaker upward price movement. Despite this downgrade in momentum, TickrTrends' derived indicators continue to assess the stock as undervalued within the Healthcare sector.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TMDX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), TMDX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is TMDX's TickrTrends verdict?
TMDX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does TMDX compare to other Healthcare stocks?
TMDX ranks #27 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is TMDX overbought or oversold?
TMDX's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
TMDX vs AVAH · TMDX vs GEHC · TMDX vs HQY · TMDX vs HSTM · TMDX vs IDXX